OPKO Health’s commercial partner for Rayaldee calcifediol ER capsules, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has initiated the commercial launch of the capsules in Germany.
VFMCRP is OPKO’s commercial partner for RAYALDEE in Europe and selected markets outside the United States. It is the first launch of RAYALDEE outside the U.S. The sales kick-off in Germany began with presentations from VFMCRP executives and prominent nephrology key opinion leaders. VFMCRP has received marketing authorizations for the drug in 11 European countries and is expecting to launch in additional markets later this year.
“The launch of RAYALDEE in Germany is a significant commercial milestone with more European countries expected to come on board, beginning with Switzerland in early March. Europe represents a large market opportunity for RAYALDEE with an estimated 26 million people suffering from stage 3 or 4 CKD. VFMCRP has significant expertise in nephrology and we are confident in their ability to market RAYALDEE successfully in Germany and other licensed territories.”Phillip Frost, M.D., Chairman and Chief Executive Officer, OPKO
SHPT causes imbalances in PTH, calcium, and phosphorus accompanied by low levels of vitamin D and is a type of hyperparathyroidism caused by something outside of the parathyroid glands.
Rayaldee is used to treat SHPT in adults with stage 3 or 4 chronic kidney disease (CKD) and low vitamin D levels. It contains an active ingredient that gradually increases vitamin D levels and decreases the levels of parathyroid hormone in the patients.